Catabasis Pharmaceuticals Inc (NASDAQ:CATB) shares are falling almost 8% amid an unfortunate setback with the firm’s MoveDMD Part B data read-out that failed …
Catabasis Pharmaceuticals Inc (NASDAQ:CATB) shares are falling 16% today after having just risen approximately 80% last week, placing the biotech stock in full …
Yesterday evening, Catabasis Pharmaceuticals Inc (NASDAQ:CATB) announced that lead candidate edasalonexent missed the primary endpoint in its Phase II proof-of-concept trial in Duchenne …
Catabasis Pharmaceuticals Inc (NASDAQ:CATB) shares lost over 70% of their value today after the company reported final results from Part B of its …
Sarepta Therapeutics Inc (NASDAQ:SRPT) just announced two Duchenne muscular dystrophy (DMD) collaborations to evaluate combotherapy with exon skipping. Sarepta will be partering with …
On Wednesday, Sarepta Therapeutics Inc (NASDAQ:SRPT) announced that it has dosed the first patient in the Phase III ESEENCE trial for patients with …
The biotech world is full of news today, and analysts are accordingly prompted to share insights on Catabasis Pharmaceuticals Inc (NASDAQ:CATB) and Alcobra Ltd (NASDAQ:ADHD). …
